secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2023-07-21T23:59:59+00:00
Accession:  0000950170-23-033845
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q2 2023 net loss $1.5M; cash $40.2M; strategic review continues
------------------------------------------------------------------------------

- Net loss $1.5M ($0.10/sh) vs $3.1M ($0.22) in Q2 2022; total operating expenses $2.0M vs $3.2M.
- Cash and equivalents $40.2M at June 30, 2023; expected to fund operations through end of 2024.
- R&D expenses fell to $0.3M from $1.5M due to rNAPc2 trial closeout and 67% workforce reduction in July 2022.
- Strategic review process ongoing with Ladenburg Thalmann; no defined timeline or guarantee of transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/0000950170-23-033845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/abio-20230721.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer